What is PMOS?

What is PMOS?

Despite what the name suggests, Polyendocrine Metabolic Ovarian Syndrome isn’t just about ovaries—or cysts, for that matter. In fact, many people diagnosed with PMOS don’t have any ovarian cysts at all. Confusing? You’re not alone. The name dates back to how the condition was first described, but science has come a long way since then. Today, we understand that PCOS is really a complex hormonal and metabolic condition that affects far more than reproductive health.

At its core, PMOS is about hormonal imbalance. When key hormones like insulin, androgens (like testosterone), and others are out of sync, they can create a domino effect throughout the body. This hormonal miscommunication can lead to irregular periods, acne, weight changes, hair loss or excess hair growth, difficulty with ovulation or fertility—and that’s just the shortlist. But here’s the thing: PMOS doesn’t follow a single pattern. Some women experience textbook symptoms. Others don’t fit the mold at all. That’s part of what makes PMOS so challenging—and why understanding your unique experience matters.

So, how can the PMOS Association help?

We’re here to offer more than definitions. We’re here to offer direction. Whether you’re newly diagnosed, still searching for answers, or years into your journey and feeling stuck, we’re committed to helping you make sense of PMOS—and make progress.

Here’s what you’ll find at PMOSA:

  • Reliable, science-backed information about what PMOS is (and isn’t)

  • 💬 Supportive communities of people who understand exactly what you’re going through

  • 🧬 Resources for navigating fertility, metabolic health, nutrition, and more

  • 🧠 Education for providers who want to better support their PMOS patients

  • 🙋‍♀️ Advocacy to make sure PMOS is recognized, researched, and respected

No fluff. No fad cures. Just real support, grounded in evidence and compassion.

At PMOSA, we believe every person with PCOS deserves to be informed, empowered, and heard. Wherever you are in your journey, we’re honored to walk with you.

pcos

pcos: Latest results from PubMed

Weight Loss Associated with Semaglutide Use is Linked to Improved Reproductive Measures in PMOS: a Proof-Of-Concept Analysis

No abstract

Published on: Sun, 07 Jun 2026 06:00:00 -0400

Authors: Melanie G Cree, Yesenia Garcia-Reyes, Allison Shapiro, Grayson Carey, Katherine Spencer, Gabriel I Medrano, Carly Faulkner, Lauryn P Roth, Patricia Huguelet, Ann E Caldwell, Victoria A Catenacci, Heidi Vanden Brink, Nanette Santoro,

Altered sulfite oxidase expression contributes to AMP-activated protein kinase-dependent mitochondrial dysfunction and metabolic dysregulation in polycystic ovary syndrome

BACKGROUND: Polycystic ovary syndrome (PCOS) is a heterogeneous disorder characterized by reproductive dysfunction and endocrine-metabolic abnormalities. However, its precise pathogenesis remains unclear. Increasing evidence indicates that ovarian granulosa cells (GCs) dysfunction and metabolic imbalance play critical roles in the initiation and progression of PCOS. This study investigated the regulatory role of the sulfite oxidase (SUOX)-AMP-activated protein kinase (AMPK) signaling axis in the...

Published on: Sat, 06 Jun 2026 06:00:00 -0400

Authors: Xiaomeng Wang, Kexin Zhang, Juan Hao, Min Zhao, Xiaofei Wang, Lin Xu,

Therapeutic potential of harmine in polycystic ovarian syndrome: regulation of TNF-α/IL-6-mediated inflammation, Nrf2/keap-1 signaling, and ovarian steroidogenesis in Sprague-Dawley rats

Polycystic ovarian syndrome (PCOS) is an intricate endocrine and metabolic disorder affecting reproductive-age women. This research focused on assessing the therapeutic potential of harmine in letrozole-induced PCOS rat model. PCOS was induced in all the groups except normal control by oral administration of letrozole (1 mg/kg) for consecutive 28 days. After confirmation of PCOS, normal and disease controls were treated with vehicle, clomiphene citrate (5.25 mg/kg) was administered as a standard...

Published on: Sat, 06 Jun 2026 06:00:00 -0400

Authors: Aqsa Ahmad, Ammara Saleem,

The Relationship Between 2D:4D Digit Ratio and Polycystic Ovary Syndrome: A Systematic Review

CONCLUSION: The majority of included studies suggest that lower 2D:4D ratios may reflect elevated prenatal androgen exposure in women with PCOS, indicating its potential as a non-invasive biomarker. Nonetheless, variability in diagnostic criteria, measurement methods, and study populations limits generalizability. Further large-scale, standardized research is required to determine clinical utility and to establish population-specific reference values.

Published on: Sat, 06 Jun 2026 06:00:00 -0400

Authors: Tuba Güner Emül, Emine Kaplan Serin,

Gut microbiota in PCOS: key microbial changes, potential mechanisms and clinical applications

CONCLUSIONS: The gut microbiota plays a pivotal role in PCOS pathophysiology and represents a novel therapeutic target. Current limitations include study heterogeneity and unresolved mechanistic details. Future research should focus on large-scale longitudinal studies and developing precise microbiota-based interventions to advance personalized management and improve outcomes in PCOS.

Published on: Fri, 05 Jun 2026 06:00:00 -0400

Authors: Shaomin Shi, Jinshu Ma, Xinhui Jing, Jia Wang, Xiaochun Sun,

MASLD, diabetes and PMOS across the female life stages

Metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes, which affect approximately 38% and 10.5%, respectively, of adults globally, intersect critically in women through polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome (PCOS), a prevalent but under-recognised cardiometabolic disorder affecting 10-13% of reproductive-age women. Beyond its reproductive consequences, PMOS promotes hepatic disease through hyperandrogenism,...

Published on: Fri, 05 Jun 2026 06:00:00 -0400

Authors: Elisabet Stener-Victorin, Sofia Carlsson, Hannes Hagström, Nayere Taebnia,

Obstructive Sleep Apnea and Risk for Thromboembolic Complication Among Patients With Polycystic Ovary Syndrome: A Retrospective Cohort Study

CONCLUSION: Among women with PCOS, comorbid OSA is associated with an increased risk of thromboembolic events, particularly pulmonary embolism. These findings support consideration of OSA screening and enhanced thromboembolic risk assessment in women with PCOS.

Published on: Fri, 05 Jun 2026 06:00:00 -0400

Authors: Jie Sung, Renin Chang, San-Nung Chen, Pei-Hsuan Lin, Chia-Jung Li, Kuan-Hao Tsui, Li-Te Lin,

Untargeted microLC-HRMS/MS for Measuring Endogenous Steroids in Mouse Plasma and Human Serum Samples Applied to Studying Polycystic Ovary Syndrome

Steroids play essential roles in regulating metabolism, response to stress, electrolyte balance, and reproductive function; however, their analysis in complex biological matrices remains challenging. Low endogenous concentrations, structural similarities, and poor ionization efficiencies can limit their detection, and conventional workflows frequently require large sample volumes and/or chemical derivatization, often restricting quantitative applications to targeted analyses. A workflow was...

Published on: Fri, 05 Jun 2026 06:00:00 -0400

Authors: Nathan Ghafari, Danko Brukner, Sherin A Nawaito, Danielle E Berbrier, Charlotte W Usselman, Nicolas Pilon, Lekha Sleno,

Non-linear saturation threshold of gonadotropin dose on cumulative live birth rates in advanced-age women with polycystic ovary syndrome: a retrospective cohort study

CONCLUSIONS: CLBR was substantially lower in advanced-age PCOS patients. A non-linear association between total Gn dose and CLBR was observed, with a plateau at approximately 1, 600 IU, although this finding may reflect confounding by indication. EMT showed a stable positive linear association with CLBR. These findings suggest that moderate stimulation with attention to endometrial preparation may warrant consideration in this population.

Published on: Fri, 05 Jun 2026 06:00:00 -0400

Authors: Yusi Han, Chunxiao Wei, Xinhua Wang, Jianwei Zhang,

Dynamic changes of Kisspeptin during controlled ovarian hyperstimulation (COH) in polycystic ovary syndrome patients and its correlation with COH outcomes

CONCLUSION: Kisspeptin may be involved in the pathological processes of ovarian hyperresponse and asynchronous follicular development in PCOS and possesses a certain predictive value for pregnancy outcomes. It provides an important basis for understanding the mechanisms of reproductive dysfunction in PCOS and for developing future multifactorial predictive models.

Published on: Fri, 05 Jun 2026 06:00:00 -0400

Authors: Lu Han, Yiran Wang, Yueying Li, Xiaoyan Li, Jing Zhang, Yan Zhang, Mingfei Zhao, Haixia Chen, Huiying Zhang, Yingmei Wang, Fengxia Xue, Wenyan Tian,

miR-148a-3p Is Elevated in Serum of PCOS Women and Modulates ALDH1A3-Retinoic Acid Signaling to Reduce Estrogen Synthesis in Granulosa-Like Cells

Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder with substantial reproductive and metabolic consequences, yet its molecular mechanisms remain incompletely understood. This study investigated circulating microRNAs (miRNAs) as potential regulators of ovarian steroidogenesis contributing to PCOS pathophysiology. Serum samples from 42 Turkish non-diabetic women with PCOS and 42 age-matched healthy controls were analyzed in a case-control design integrating small RNA sequencing...

Published on: Thu, 04 Jun 2026 06:00:00 -0400

Authors: Emre Murat Altinkilic, Kay Sara Sauter, Therina du Toit, Pamela Nicholson, Önder Sakin, Rukset Attar, Christa E Flück,

From PCOS to PMOS: Beyond ovarian morphology to neuroendocrine networks

No abstract

Published on: Thu, 04 Jun 2026 06:00:00 -0400

Authors: Bulent Okan Yildiz,

Vitamin D status tracks inflammation perfusion and pregnancy in polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) is characterized by metabolic and inflammatory heterogeneity, but the relative associations of vitamin D status and insulin resistance with inflammatory activation, uterine perfusion, and reproductive outcomes remain unclear. We analyzed a prospective discovery cohort of 580 affected women and 332 controls, followed by multicenter retrospective external validation in 750 additional affected women. Multivariable linear and logistic regression analyses showed that...

Published on: Thu, 04 Jun 2026 06:00:00 -0400

Authors: Kexin Wang, Ruifang Wang, Zhuhua Cai, Junxian Ma, Guosheng Li, Fang Wang,

Expression of Concern on "The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients"

The Editor in Chief and the Publisher are issuing an expression of concern regarding the following article: Minozzi M, Nordio M, Pajalich R. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci. 2013 Feb;17(4):537-40. PMID: 23467955. Post-publication concerns have been raised regarding the reliability of certain data and statistical analyses, including possible...

Published on: Thu, 04 Jun 2026 06:00:00 -0400

Authors: No Authors listed,

Out of pocket expenditure incurred by couples seeking infertility services at tertiary level facilities in India

Background and objectives Diagnosis and treatment of infertility, mostly sought at tertiary facilities, contribute to substantial out-of-pocket expenditure (OOPE). This study estimated OOPE among couples seeking care for endometriosis, male infertility, polycystic ovary syndrome (PCOS), tubal factor, and uterine factor, including costs of diagnosis, management, and intrauterine insemination (IUI). Methods A cross-sectional study was conducted across five tertiary healthcare facilities (three...

Published on: Thu, 04 Jun 2026 06:00:00 -0400

Authors: Asim Kumar Padhan, Prerana Patil, Akshita Vikani, Deepshikha Sharma, Oshima Sachin, Biju Somen, Bhavani Shankara Bagepally, Renu Tanwar, Vanita Suri, Radha V, Anitha M, Ramesh P, Deepti Shrivastava, Sukhpreet Patel, Shankar Prinja, Beena Joshi,